SavedAdd your journal

Journals / Ankara Üniversitesi Eczacılık Fakültesi Dergisi / 2021 / Cilt: 45 - Sayı: 2

CURRENT APPROACHES IN PULMONARY ARTERIAL HYPERTENSION TREATMENT

PULMONER ARTERİYEL HİPERTANSİYON TEDAVİSİNDE GÜNCEL YAKLAŞIMLAR

Cenk YILDIZ
Burcu DEVRİM
Pages
379–399
Publication Date
2021-05-31
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In addition, various methods for the use of targeted drug delivery systems have been evaluated to improve the efficacy of approved and investigational drugs.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Pulmonary arterial hypertension (PAH) is a cronic disease with high morbidity and mortality.
📊
Key Findings & Data:Although the applied treatment strategies provide an improvement in the quality of life of the patients, PAH continues to be a life-limiting disease for most patients, without the possibility of treatment.
💡
Conclusion & Impact:In addition, various methods for the use of targeted drug delivery systems have been evaluated to improve the efficacy of approved and investigational drugs.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Drug delivery systems · pulmonary arterial hypertension · targeted therapy

Abstract

Objective: Pulmonary arterial hypertension (PAH) is a cronic disease with high morbidity and mortality. Although the applied treatment strategies provide an improvement in the quality of life of the patients, PAH continues to be a life-limiting disease for most patients, without the possibility of treatment. The most important problems encountered in the current therapies for PAH are patient incompliance and off-target side effects. In this review, the potential of various new molecular pathways such as rhoA/rho kinase, tyrosine kinase, endothelial progenitor cells, vasoactive intestinal peptide and miRNA are discussed in the treatment of PAH. In addition, various methods for the use of targeted drug delivery systems have been evaluated to improve the efficacy of approved and investigational drugs.

Özet

Amaç: Pulmoner arteriyel hipertansiyon (PAH), yüksek morbidite ve mortaliteye sahip kronik bir hastalıktır. PAH için uygulanan tedavi stratejileri hastaların yaşam kalitesinin iyileşmesini sağlamakla birlikte, hastaların büyük çoğunluğu için PAH, tedavi olasılığı olmayan hayatı sınırlayan bir hastalık olmaya devam etmektedir. Mevcut PAH tedavisinde karşılaşılan en önemli sorunlar hasta uyuncunun düşük olması ve yan etkilerin görülmesidir. Bu derlemede, PAH tedavisinde rhoA/rho kinaz, tirozin kinaz, endotel progenitör hücreleri, vazoaktif bağırsak peptiti ve miRNA gibi çeşitli yeni moleküler yolakların potansiyeli tartışılmıştır. Ayrıca, tedavide kullanılmak üzere onaylanmış ve inceleme aşamasında olan etkin maddelerin etkinliğini artırmak için hedeflendirilmiş ilaç taşıyıcı sistemlerin kullanımına yönelik çeşitli yöntemler değerlendirilmiştir.

🔖

Cite This Article

YILDIZ, C., DEVRİM, B. (2021). CURRENT APPROACHES IN PULMONARY ARTERIAL HYPERTENSION TREATMENT. Ankara Üniversitesi Eczacılık Fakültesi Dergisi, Cilt: 45 - Sayı: 2, 379–399. https://ajindex.com/articles/194930

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Zolty, R. (2020). Pulmonary arterial hypertension specific therapy: The old and the new. Pharmacology & Therapeutics, 214(2020), 1-18
  2. Galie, N., Humbert, M., Vachiery, J., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Noordegraaf, A.V., Beghetti, M., Ghofrani, A., Sanchez, M.A.G., Hansmann, G., Klepetko, W., Lancellotti, P., Matucci, M., McDonagh, T., Pierard, L.A., Trindade P.T., Zompatori, M., Hoeper, M. (2016). Guidelines on diagnosis and treatment of pulmonary hypertension. European Heart Journal, 37, 67-119
  3. Türk Toraks Derneği Web site. Retrieved February 5, 2020. from
  4. Öztürk, Ö., Şahin, Ü. (2009). Pulmoner hipertansiyon: Tanı ve tedavisi. Süleyman Demirel Üniversitesi Tıp Fakültesi Dergisi, 16 (1), 39-47
  5. Demir, R., Küçükoğlu, M.S. (2010). Pulmoner arter hipertansiyonunda egzersiz kapasitesinin değerlendirilmesi. Türk Kardiyoloji Derneği Arşivi, 38(8), 580-588
  6. Vaidya, B., Gupta, V. (2015). Novel therapeutic approaches for pulmonary arteriel hypertension: Unique molecular targets to site-specific drug delivery. Journal of Controlled Release, 211, 118- 133
  7. Gunt, C., Çekmen, N. (2016). Pulmoner hipertansiyon ve weaning. Türk Yoğun Bakım Dergisi, 14, 68-79
  8. Spiekerkoetter, E., Kawut, S.M., de Jesus Perez, V.A. (2019). New and emerging therapies for pulmonary arterial hypertension. Annual Review of Medical, 70, 45-59
  9. Çörtük, M., Çetinkaya, E. (2017). Pulmoner arteriyel hipertansiyonda prostasiklin analogları ve prostaglandin reseptör agonistleri. Türkiye Klinikleri Akciğer Arşivi, 18(1), 17-24
  10. Kılıçkesmez, K., Küçükoğlu, M.S. (2010). Pulmoner arteriyel hipertansiyon tedavisinde fosfodiesteraz-5 inhibitörleri. Anadolu Kardiyoloji Dergisi, 10(2), 16-18
  11. Gessler, T. (2018). Inhalation of repurposed drugs to treat pulmonary hypertension. Advanced Drug Delivery Reviews, 133, 34-44
  12. O’Connell, C., Amar, D., Boucly, A., Savale, L., Jais, X., Chaumais, M., Montani, D., Humbert, M., Simonneau, G., Sitbon, O. (2016). Comparative safety and tolerability of prostacyclins in pulmonary hypertension. Drug Safety, 39, 287-294
  13. Ishihara, T., Hayashi, E., Yamamoto S., Kobayashi, C., Tamura, Y., Sawazaki, R., Tamura, F., Tahara, K., Kasahara, T., Ishihara, T., Takenaga, M., Fukuda, K., Mizushima, T. (2015). Encapsulation of beraprost sodium in nanoparticles: Analysis of sustained release properties, targeting abilities and pharmacological activities in anim